Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» $690M deal in peril after Lilly ends mid-stage studies
$690M deal in peril after Lilly ends mid-stage studies
$690M deal in peril after Lilly ends mid-stage studies
Submitted by
admin
on February 21, 2018 - 9:43am
Source:
Biopharma Dive
News Tags:
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224
Headline:
$690M deal in peril after Lilly ends mid-stage studies
Do Not Allow Advertisers to Use My Personal information
